# PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma

> **NCT06696742** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 60 (estimated)

## Conditions studied

- Bladder (Urothelial, Transitional Cell) Cancer

## Interventions

- **DRUG:** Clostridium Butyricum Tablets
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT06696742
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-01
- **Primary completion:** 2029-02-01
- **Final completion:** 2029-02-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06696742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06696742, "PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06696742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*